|
2022
|
Invention
|
Orally active leukemia inhibitory factor (lif) antagonists for the treatment of cancer.
Describe... |
|
|
Invention
|
Orally active leukemia inhibitory factor (lif) antagonists for the treatment of cancer. Described... |
|
2020
|
Invention
|
Hormonal contraception using a vaginal ring which releases estriol and trimegestone.
The inventi... |
|
|
Invention
|
Hormonal contraception using a vaginal ring which releases estriol and trimegestone. The inventio... |
|
2019
|
Invention
|
Drug device combination for the effective treatment of incontinence in women.
In embodiments des... |
|
|
Invention
|
Drug device combination for the effective treatment of incontinence in women. In embodiments desc... |
|
|
Invention
|
Lif/lifr antagonist in oncology and nonmalignant diseases.
Described herein are methods of using... |
|
|
Invention
|
Lif/lifr antagonist oncology and nonmalignant diseases. Described herein are methods of using com... |
|
|
Invention
|
Hormonal contraception using a vaginal ring which releases estriol.
A variety of different intra... |
|
|
Invention
|
Targeted delivery of progestins and estrogens via vaginal ring devices for fertility control and ... |
|
|
Invention
|
Estrogen prodrugs and methods of administering estrogen prodrugs.
Disclosed herein is an intrava... |
|
|
Invention
|
Estrogen prodrugs and methods of administering estrogen prodrugs. Disclosed herein is an intravag... |
|
2018
|
Invention
|
Longer-acting progestin prodrug contraceptives. Described herein are progestin compounds that hav... |
|
|
Invention
|
Cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of... |
|
2017
|
Invention
|
Progesterone antagonists.
Described herein are compounds which either act as pure antiprogestins... |
|
|
Invention
|
Pro-drug forming compounds. 2 are described herein. Compounds having this general structure were ... |
|
|
Invention
|
Intravaginal drug delivery device.
Described herein is an intravaginal drug delivery system. In ... |
|
2016
|
Invention
|
Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatm... |
|
2015
|
Invention
|
Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effe... |
|
2014
|
Invention
|
Pro-drug forming compounds. Various prodrug compounds having the general structure: Active agent-... |
|
|
Invention
|
Imidazolyl progesterone antagonists. Described herein are imidazolyl compounds which either act a... |
|
|
Invention
|
Imidazolyl progesterone antagonists. Described herein are imidazolyl compounds that exhibit proge... |
|
2012
|
Invention
|
Methods for the preparation of etonogestrel and desogestrel. Described herein is a process for th... |
|
|
Invention
|
Progesterone antagonists. Described herein are compounds which either act as pure antiprogestins ... |
|
2011
|
Invention
|
Methods for the preparation of etonogestrel and desogestrel.
Described herein is a process for t... |
|
|
Invention
|
Intravaginal drug delivery device. Described herein is an intravaginal drug delivery system. In a... |
|
2010
|
Invention
|
Progesterone antagonists spiro condensed in position 17 with a difluoromethylene- substituted per... |
|
|
Invention
|
Methods for the preparation of drospirenone. Described herein are methods of making drospirenone.... |
|
|
Invention
|
Progesterone antagonists. Described herein are compounds which exhibit progesterone antagonistic ... |
|
2009
|
Invention
|
Progestational 3-(6,6-ethylene-17b-hydroxy-3-oxo-17a-pregna-4-ene-17a -yl) propionic acid g-lacto... |
|
|
Invention
|
Progestational 3-(6,6-ethylene-17b-hydroxy-3-oxo-17a-pregna-4-ene-17a-yl)propionic acid g-lactone... |
|
|
Invention
|
Estriol formulations.
Disclosed herein are oral dosage forms and methods of their use, in partic... |
|
|
Invention
|
Estriol formulations. Disclosed herein are oral dosage forms and methods of their use, in particu... |
|
|
Invention
|
Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and furt... |
|
|
Invention
|
Oral contraceptive dosage forms and methods of making such dosage forms.
Disclosed herein are or... |
|
|
Invention
|
Bismethylene-17a carbolactones and related uses. Described herein are bismethylene-17α carbolacto... |
|
2008
|
P/S
|
Pharmaceutical products for female health care, namely, pharmaceutical products for the treatment... |
|
|
P/S
|
Pharmaceutical products for female health care, namely, pharmaceutical products for female fertil... |
